Alberta Health Services (AHS) is taking steps to minimize patient impacts from a shortage of the injectable drug sodium bicarbonate.
Like other jurisdictions across North America, AHS is facing a shortage of sodium bicarbonate injection, due to a manufacturing issue by producer Hospira Inc., a Pfizer company. The drug is used in critical care and other urgent clinical areas. It is commonly used in life-threatening situations when the blood becomes too acidic.
AHS will continue to do everything possible to minimize patient impacts from drug shortages. Effective and safe patient care is always our first priority.
This is a serious issue and AHS is working hard to mitigate the effects of the shortage. AHS is considering all options and will do all it can to ensure patients receive the best quality care possible.
Updates on the shortage will be posted on this page.